Glucotrack Announces Reverse Stock Split1-for-20 reverse stock split to become effective as of the opening of trading on February 4, 2025
Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial OfficerIndustry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetes
Glucotrack Announces ISO 13485:2016 CertificationISO Certification highlights commitment to quality for continuous blood glucose monitor
Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory AffairsNew hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes
Glucotrack to Present at TechBio Showcase™ 2025Presentation to feature an update on the Company’s novel continuous blood glucose monitor for patients with diabetes
GLUCOTRACK ANNOUNCES THE HIRING OF DR. MARK TAPSAKINDUSTRY VETERAN TO LEAD NEW CONTINUOUS GLUCOSE MONITORING R&D PROGRAM
GLUCOTRACK TO BEGIN RESEARCH & DEVELOPMENT OF NOVEL CONTINUOUS GLUCOSE MONITORING SYSTEMRutherford, NJ, Oct. 10, 2022 (GLOBE NEWSWIRE) -- GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), a non-invasive device and digital health platform for measuring glucose levels in people with Type 2 diabetes and prediabetes, announced today it is expanding its product pipeline with the commencement of a new R&D program for a long-term continuous glucose monitor.
